MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Medical College of Wisconsin
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Senti Biosciences
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
Ohio State University Comprehensive Cancer Center
Montefiore Medical Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Children's Oncology Group
Foghorn Therapeutics Inc.
Novo Nordisk A/S
M.D. Anderson Cancer Center
University of Florida
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Northwestern University
Nkarta, Inc.
BerGenBio ASA
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Ascentage Pharma Group Inc.
Heinrich-Heine University, Duesseldorf
First Affiliated Hospital of Zhejiang University
IRCCS San Raffaele
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
University of Washington
Rush University Medical Center
Children's Oncology Group
University of Southern California
University of Washington